Moteur de recherche d’entreprises européennes
Financement de l’UE (8 265 080 €) : Des fragments aux liants de haute affinité interfacant la biologie structurale intégrée, la chimie médicinale et l’intelligence artificielle Hor13/01/2023 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Des fragments aux liants de haute affinité interfacant la biologie structurale intégrée, la chimie médicinale et l’intelligence artificielle
Fragment-Screen will develop innovative instrumentation, workflows and experimental and computational methodologies for fragment-based drug discovery (FBDD) enabling access to early phase structure-based drug discovery for all biological targets and for scientists both in industry and academia. The established workflows will use structural biology insights and associated data to feed artificial intelligence (AI) methodology to guide medicinal chemistry in drug development. Fragment-Screen brings together scientists from four ESFRI Landmark research infrastructures (RIs): ESRF (the European synchrotron) and the distributed RIs EU-OPENSCREEN ERIC (medicinal chemistry), ELIXIR (data resources for life science) under the coordination of Instruct-ERIC (integrated structural biology) and seven industry partners in scientific instrumentation and computational and AI sectors including SMEs to remove crucial bottlenecks in early phase drug discovery. The new instrumentation and workflows will be available at European RIs, while the new instruments will be commercialised to increase the technological competitiveness of European industry in drug design and the attractiveness of structural biology RIs for the pharmaceutical and biotech sectors. Fragment-Screen will implement open science approaches in early drug discovery to maximise the impact of screening campaigns. Generated data will be made accessible so that iterative cycles applying AI will improve response times for drug discovery. We will create a framework for the objective and independent evaluation of AI in drug design to identify critical developments in this thriving research field. Methodologies for rigorous cross-validation will be established through demonstrator and pilot studies and results will be disseminated to the large scientific communities affiliated to the European RIs and beyond.
https://cordis.europa.eu/project/id/101094131
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Astex Therapeutics Ltd., Cambridge, Royaume Uni.